Peripherally Restricted, Highly Potent, Selective, Aqueous-Soluble EP2 Antagonist with Anti-Inflammatory Properties.

Peripherally Restricted, Highly Potent, Selective, Aqueous-Soluble EP2 Antagonist with Anti-Inflammatory Properties.
复制标题

DOI:
10.1021/acs.molpharmaceut.8b00764
复制
发表时间:
2018-12-03
影响因子:
4.9
通讯作者:
Amaradhi R
Amaradhi R
中科院分区:
医学2区
文献类型:
--
作者:
Ganesh T;Banik A;Dingledine R;Wang W;Amaradhi R

文献摘要

参考文献

被引文献

相似文献

前列腺素E2受体EP2在生理学以及多种病理状况中发挥着重要作用。研究表明,在慢性外周和中枢神经系统疾病以及癌症模型中,EP2具有促炎作用。因此,用小分子靶向EP2受体可能是治疗炎症性疾病和癌症的一种治疗策略。我们最近报道了一类新型的EP2受体竞争性拮抗剂。然而,早期的先导化合物对DP1前列腺素受体选择性较低,血浆半衰期适中,水溶性低,这使得它们在疾病动物模型中测试时并非最佳选择。我们现在报道一种新型化合物TG8 - 69,它具有合适的类药性质。我们介绍了该化合物的合成、先导化合物优化研究、药理学特性以及抗炎特性,这些都支持其用于包括类风湿性关节炎、子宫内膜异位症和癌症在内的慢性外周炎症性疾病,在这些疾病中EP2似乎起着致病作用。
The prostaglandin E2 receptor, EP2, plays an important role in physiology and in a variety of pathological conditions. Studies indicate that EP2 is pro-inflammatory in chronic peripheral and central nervous system disease and cancer models. Thus, targeting the EP2 receptor with small molecules could be a therapeutic strategy for treating inflammatory diseases and cancer. We recently reported a novel class of competitive antagonists of the EP2 receptor. However earlier leads displayed low selectivity against the DP1 prostanoid receptor, moderate plasma half-life and low aqueous solubility, which renders them sub-optimal for testing in animal models of disease. We now report a novel compound TG8–69, which has suitable drug-like properties. We present synthesis, lead-optimization studies, pharmacological characterization, and anti-inflammatory properties of this compound that support its use in chronic peripheral inflammatory diseases including rheumatoid arthritis, endometriosis and cancer, in which EP2 appears to play a pathogenic role.
DOI: 10.1016/j.neuropharm.2015.01.017
发表时间: 2015-06
期刊: Neuropharmacology
影响因子: 4.7
作者:
Rojas A;Ganesh T;Lelutiu N;Gueorguieva P;Dingledine R
通讯作者: Dingledine R
DOI: 10.1161/circresaha.107.165936
发表时间: 2008-04-25
影响因子: 20.1
作者:
Arehart, Eric;Stitham, Jeremiah;Hwa, John
通讯作者: Hwa, John
DOI: 10.1021/ac9912247
发表时间: 2000-04-15
影响因子: 7.4
作者:
Bevan, CD;Lloyd, RS
通讯作者: Lloyd, RS
DOI: 10.1016/j.neuropharm.2016.07.028
发表时间: 2016-11-01
期刊: NEUROPHARMACOLOGY
影响因子: 4.7
作者:
Rojas, Asheebo;Ganesh, Thota;Dingledine, Raymond
通讯作者: Dingledine, Raymond
DOI: 10.1021/acs.jmedchem.5b00567
发表时间: 2015-07-09
影响因子: 7.3
作者:
Fox, Brian M.;Beck, Hilary P.;Olson, Steven H.
通讯作者: Olson, Steven H.